ArcticZymes Technologies Sell Shares to Support Employee Share Purchase Program

04 Dec 2025 07:30 CET

Tromsø, Norway, December 4th, 2025 - Reference is made to the stock exchange
announcement published by ArcticZymes Technologies ASA (the "Company", OSE: AZT)
on 28 November 2025 announcing completion of share buy-back to support Employee
Share Purchase Program

In alignment with the guidelines for the program, 31.365 treasury shares have
been sold to employees of the Company.  The shares were acquired for NOK 22.5037
per share and are traded for NOK 19.128. This is a 15% discount on the
acquisition price. The shares have a one-year lock-up period before they can be
traded.

Following completion of the sale, the Company holds 0 own shares.

Certain primary insiders have participated in the program and have acquired a
total of 6.600 shares. The number of shares purchased by each primary insider,
together with their new total shareholding following the transaction, is as
follows:

· Michael Akoh acquires 1.100 shares and will hold 8.760 shares in total.
· Børge Sørvoll acquires 1.100 shares and will hold 101.528 shares in total.
· Olav Lanes acquires 1.100 shares and will hold 8.100 shares in total.
· Marit Sjo Lorentzen acquires 1.100 shares and will hold 29.831 shares in
total.
· Grethe Ytterstad acquires 1.100 shares and will hold 8.369 shares in total.
· Lill Hege Henriksen acquires 1.100 share and will hold 4.188 shares in
total.

This information is made public pursuant to the EU Market Abuse Regulation and
subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian
Securities Trading Act.

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll Tel +47 952 90187
ir@arcticzymes.com

About ArcticZymes Technologies ASA

Headquartered in Tromsø, Norway, ArcticZymes Technologies ASA is a publicly
listed, leading provider of novel and high-quality enzymes for use in molecular
research, diagnostics, and biomanufacturing. With over 30 years of expertise,
the company develops and manufactures salt-active nucleases and other specialty
enzymes inspired by the Arctic environment, enabling robust performance under
demanding process conditions. ArcticZymes is certified to ISO 13485 and
manufactures under relevant ICH GMP standards.
For more information, visit www.arcticzymes.com.

More information:
Access the news on Oslo Bors NewsWeb site

661195_KRT_1500_Des_BSO.pdf
661195_KRT_1500_Des_GY.pdf
661195_KRT_1500_Des_MSL.pdf
661195_KRT_1500_Des_LHH.pdf
661195_KRT_1500_Des_MA.pdf
661195_KRT_1500_Des_OL.pdf